Body Composition and the Components of Metabolic Syndrome in Type 2 Diabetes: The Roles of Disease Duration and Glycemic Control

Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research

Related Links:

Authors: Afrisham R, Paknejad M, Ilbeigi D, Sadegh-Nejadi S, Gorgani-Firuzjaee S, Vahidi M Abstract INTRODUCTION: Fetuin-A serves a dual function; its high levels are associated with metabolic syndrome, type 2 diabetes, obesity, insulin resistance, and nonalcoholic fatty liver disease and on the other hand, it serves as a potent inhibitor of vascular ectopic calcification. Because of the opposing findings, the aim of the current study was to investigate serum fetuin-A levels in military personnel males with coronary artery disease (CAD). METHODS: In the case-control study, anthropometric and biochemical paramet...
Source: Endocrine, Metabolic and Immune Disorders Drug Targets - Category: Drugs & Pharmacology Tags: Endocr Metab Immune Disord Drug Targets Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Metabolic syndrome (MetS) is a condition characterized by the co-occurrence of metabolic risk factors for both type 2 diabetes mellitus (T2DM) and cardiovascular disease (CVD) [1,2]. It includes various combinations of abdominal obesity, elevated fasting plasma glucose (FPG), atherogenic dyslipidemia with elevated triglyceride levels, low high-density lipoprotein (HDL) cholesterol levels, and elevated blood pressure (BP) [3]. The modified National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) definition is one of the most widely used criteria for MetS [4], because it uses available clinical variabl...
Source: Diabetes Research and Clinical Practice - Category: Endocrinology Authors: Source Type: research
ConclusionsMetabolic health and obesity fluctuated within a relatively short period of four to five years. Although the impact was much greater for MetS than for obesity, the cumulative duration of both obesity and MetS was associated with an increased risk of T2D in a dose ‐response manner. Therefore, continuously maintaining metabolic health and normal weight is crucial to prevent incident T2D.
Source: Journal of Diabetes Investigation - Category: Endocrinology Authors: Tags: ORIGINAL ARTICLE Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy Source Type: research
More News: Diabetes | Diabetes Type 2 | Eating Disorders & Weight Management | Endocrinology | Metabolic Syndrome | Obesity